Efineptakin alfa (NT-17) 是一种长效重组人IL-7。 Efineptakin alfa 支持人和小鼠体内 CD4+和 CD8+细胞的增殖和存活。 Efineptakin alfa 可用于胶质母细胞瘤的研究。
| 生物活性 | Efineptakin alfa (NT-17) is a long-acting recombinant humanIL-7. Efineptakin alfa supports the proliferation and survivalCD4+and CD8+cells in both human and mice. Efineptakin alfa can be used for glioblastoma research[1]. |
| IC50& Target | |
体内研究
(In Vivo) | Efineptakin alfa (10mg /kg，肌肉注射，单次) 联合 SLC-3010 (1.8 mg/kg，静脉注射，单次)抑制 MC38 荷瘤小鼠的肿瘤生长[2]。
Efineptakin alfa (10 mg/kg) 在原位胶质瘤荷瘤小鼠中，可减轻放疗相关的淋巴细胞减少，增加全身和肿瘤中的细胞毒性 CD8 T 淋巴细胞，并提高原位胶质瘤荷瘤小鼠的存活率[1]。
| Animal Model: | C57BL/6 mice bearing intracranial tumors (GL261 or CT2A)[1] | | Dosage: | 10 mg/kg | | Administration: | On the final day of RT (radiotherapy, 1.8 Gy/day × 5 days) completion | | Result: | Increased T lymphocytes in the lymph nodes, thymus, and spleen, enhanced IFNγ production, and decreased Tregs in the tumor which was associated with a significant increase in survival. Enhanced central memory and effector memory CD8 T cells in lymphoid organs and tumor. Decreased progenitor cells in the bone marrow. |
|
| CAS 号 | |
| 储存方式 | Please store the product under the recommended conditions in the Certificate of Analysis. |
